Table 2.
Biologics switching publications up tp 30 June 2017 (hierarchy of listing: disease indication, year of publication, type of publication, and sample size)
| Citation no. | Study | Year | Publication type | Biologics | N | Duration |
|---|---|---|---|---|---|---|
| Larger biologics | ||||||
| Inflammatory bowel disease (IBD) | ||||||
| 1 | Fiorino et al. | 2017 | Journal Article | Infliximab (CT-P13) | 547 | 4.3 ± 2.8 months |
| 2 | Razanskaite et al. | 2017 | Journal Article | Infliximab (CT-P13) | 143 | 12 months |
| 3 | Kolar et al. | 2017 | Journal Article | Infliximab (CT-P13) | 74 | 56 weeks |
| 4 | Jahnsen and Jørgensen | 2017 | Journal Article | Infliximab (CT-P13) | 56 | 12 months |
| 5 | Plevris et al. | 2017 | Abstract | Infliximab (CT-P13) | 160 | 12 months |
| 6 | Eberl et al. | 2017 | Abstract | Infliximab (CT-P13) | 78 | 16 weeks |
| 7 | Choe et al. | 2017 | Abstract | Infliximab (CT-P13) | 74 | 30 weeks |
| 8 | Rodríguez Glez et al. | 2017 | Abstract | Infliximab (CT-P13) | 72 | 12 months |
| 9 | Soret et al. | 2017 | Abstract | Infliximab (CT-P13) | 63 | 9 months |
| 10 | Nugent et al. | 2017 | Abstract | Infliximab (CT-P13) | 52 | 12 months |
| 11 | Kang et al. | 2017 | Abstract | Infliximab (CT-P13) | 38 | 1 year |
| 12 | Puente et al. | 2017 | Abstract | Infliximab (CT-P13) | 36 | 16 weeks |
| 13 | Gompertz et al. | 2017 | Abstract | Infliximab (CT-P13) | 30 | 24 weeks |
| 14 | Buer et al. | 2017 | Journal Article | Infliximab (CT-P13) | 143 | 6 months |
| 15 | Sieczkowska et al. | 2016 | Journal Article | Infliximab (CT-P13) | 39 | 67 weeks |
| 16 | Hernández et al. | 2016 | Abstract | Infliximab (BS - No info) | 72 | 6 months |
| 17 | Hlavaty et al. | 2016 | Abstract | Infliximab (CT-P13) | 25 | 48 weeks |
| 18 | Hamanaka et al. | 2016 | Abstract | Infliximab (P329) | 20 | 24 weeks |
| 19 | Park et al. | 2015 | Journal Article | Infliximab (CT-P13) | 173 | 30 weeks |
| 20 | Jung et al. | 2015 | Journal Article | Infliximab (CT-P13) | 110 | 54 weeks |
| 21 | Kang et al. | 2015 | Journal Article | Infliximab (CT-P13) | 17 | 16 weeks |
| 22 | Smits et al. | 2017 | Journal Article | Infliximab (CT-P13) | 83 | 12 months |
| Crohn’s disease (CD) | ||||||
| 23 | Choe et al. | 2017 | Abstract | Infliximab (CT-P13) | 204 | 30 weeks |
| 24 | Strik et al. | 2017 | Abstract | Infliximab (CT-P13) | 61 | 16 weeks |
| 25 | Guerra Veloz et al. | 2016 | Abstract | Infliximab (CT-P13) | 75 | 6 months |
| 26 | Sieczkowska et al. | 2016 | Abstract | Infliximab (BS) | 16 | No information |
| 27 | Kierkus | 2015 | Abstract | Infliximab (CT-P13) | 32 | 32 weeks |
| Ulcerative colitis (UC) | ||||||
| 28 | Guerra Veloz et al. | 2016 | Abstract | Infliximab (CT-P13) | 40 | 6 months |
| Rheumatoid arthritis (RA) and rheumatoid disease | ||||||
| 29 | Park et al. | 2017 | Journal Article | Rituximab (CT-P10) | 58 | 56 weeks |
| 30 | Yoo et al. | 2016 | Journal Article | Infliximab (CT-P13) | 302 | 102 weeks |
| 31 | Tanaka et al. | 2017 | Journal Article | Infliximab (CT-P13) | 71 | 110 weeks |
| 32 | Yazici et al. | 2016 | Abstract | Infliximab (CT-P13) | 1044 | 12 months |
| 33 | Weinblatt et al. | 2016 | Abstract | Adalimumab (SB5) | 508 | 52 weeks |
| 34 | Cohen et al. | 2016 | Abstract | Adalimumab (ABP-501) | 466 | 72 weeks |
| 35 | Smolen et al. | 2016 | Abstract | Infliximab (SB2) | 396 | 78 weeks |
| 36 | Emery et al. | 2016 | Abstract | Etanercept (SB4) | 245 | 100 weeks |
| 37 | Gentileschi et al. | 2016 | Letter | Infliximab (BS) | 23 | 1.71 months |
| 38 | Nikiphorou et al. | 2015 | Journal Article | Infliximab (CT-P13) | 39 | 13 months |
| Ankylosing spondylitis (AS) | ||||||
| 39 | Park et al. | 2016 | Journal Article | Infliximab (CT-P13) | 174 | 102 weeks |
| Spondyloarthritis (SpA) | ||||||
| 40 | Benucci et al. | 2017 | Journal Article | Infliximab (CT-P13) | 41 | 6 months |
| Psoriasis (PsO) | ||||||
| 41 | Griffiths et al. | 2016 | Journal Article | Etanercept (GP2015) | 531 | 52 weeks |
| 42 | Gooderham et al. | 2016 | Abstract | Adalimumab (ABP-501) | 350 | 52 weeks |
| 43 | Garofalo et al. | 2016 | Abstract | Infliximab (CT-P13) | 45 | 12 weeks |
| 44 | Dapavo et al. | 2016 | Abstract | Infliximab (CT-P13) | 35 | No information |
| 45 | Ricceri et al. | 2016 | Abstract | Infliximab (CT-P13) | 22 | 10 months |
| Human volunteers (HV) | ||||||
| 46 | Lee et al. | 2016 | Journal Article | Etanercept (SB4) | 138 | 7 weeks |
| 47 | Afonso et al. | 2016 | Abstract | Etanercept (GP2015) | 54 | 28 days |
| Combined indication studies | ||||||
| 48 | Vergara-Dangond et al. | 2017 | Journal Article | Infliximab (CT-P13) | 13 | 4 Cycles Trt |
| 49 | Batticciotto et al. | 2016 | Abstract | Infliximab (CT-P13) | 36 | 6 months |
| 50 | Holroyd et al. | 2016 | Abstract | Infliximab (CT-P13) | 56 | 5 months |
| 51 | Abdalla et al. | 2017 | Journal Article | Infliximab (CT-P13) | 34 | 15.8 months |
| 52 | Glintborg et al. | 2017 | Journal Article | Infliximab (CT-P13) | 802 | 413 days |
| 53 | Tweehuysen et al. | 2016 | Abstract | Infliximab (BS) | 192 | 6 months |
| 54 | Jørgensen et al. | 2017 | Journal Article | Infliximab (CT-P13) | 482 | 52 weeks |
| Smaller biologics | ||||||
| Chronic kidney disease (CKD) | ||||||
| 55 | Harzallah et al. | 2015 | Journal Article | rHuEPO (Epoetin Alfa) | 53 | 43 days |
| 56 | Wiecek et al. | 2010 | Journal Article | rHuEPO (Epoetin Zeta) | 582 | 24 weeks |
| 57 | Haag-Weber et al. | 2009 | Journal Article | rHuEPO (HX575) | 478 | 56 weeks |
| 58 | Frei et al. | 2009 | Journal Article | rHuEPO Epoetin Delta SC | 478 | 1 year |
| 59 | Turner et al. | 2009 | Abstract | rHuEPO (HX575) | 51 | 6 months |
| 60 | Wizemann et al. | 2008 | Journal Article | rHuEPO (Epoetin Zeta) | 313 | 52 weeks |
| 61 | Smith et al. | 2007 | Journal Article | rHuEPO (Epoetin Delta) | 121 | 4 weeks |
| End-stage renal disease (ESRD) | ||||||
| 62 | Lonnemann and Wrenger | 2011 | Journal Article | rHuEPO (Epoetin Zeta) | 17 | 6 months |
| 63 | Krivoshiev et al. | 2010 | Journal Article | rHuEPO (Epoetin Zeta) | 462 | 82 weeks |
| Hemodialysis (HD) | ||||||
| 64 | Minutolo et al. | 2016 | Journal Article | rHuEPO (HX575 or SB309) | 149 | 24 weeks |
| 65 | Ode et al. | 2011 | Abstract | rHuEPO (HX575) | 1,695 | 6 months |
| 66 | Milutinovic et al. | 2006 | Journal Article | rHuEPO (Epoetin Omega) | 77 | 12 weeks |
| 67 | Bren et al. | 2002 | Journal Article | rHuEPO (Epoetin Omega) | 38 | 48 weeks |
| Growth hormone disorders (GHD) | ||||||
| 68 | Rashid et al. | 2014 | Journal Article | GH | 103 | 30 months |
| 69 | Gila and Garcia | 2014 | Journal Article | GH | 20 | 36 months |
| 70 | Flodmark et al. | 2013 | Journal Article | GH | 102 | 3 years |
| 71 | Ullah et al. | 2012 | Abstract | GH | 14 | 9 months |
| 72 | Romer et al. | 2011 | Journal Article | GH | 166 | 84 months |
| 73 | Farias et al. | 2010 | Journal Article | GH | 24 | 28 days |
| 74 | Bidlingmaier et al. | 2006 | Journal Article | GH (sustained-release GH)] | 9 | 3 months |
| 75 | Vahl et al. | 1996 | Journal Article | GH | 18 | 3 weeks |
| 76 | Laursen et al. | 1993 | Journal Article | GH | 14 | 5 weeks |
| Human volunteers (HV) | ||||||
| 77 | Fuhr et al. | 2010 | Journal Article | GH | 67 | 7 days |
| 78 | Waller et al. | 2010 | Journal Article | Filgrastim | 50 | 33 days |
| 79 | Stanhope et al. | 2010 | Journal Article | GH | 48 | 24 months |
| 80 | Cheung et al. | 2000 | Journal Article | rHuEPO | 48 | 30 days |
| 81 | Liedert et al. | 2010 | Journal Article | GH | 30 | ~ 1 months |
| 82 | Kim et al. | 2010 | Journal Article | rHuEPO (Epoetin alfa) | 20 | ~ 6 weeks |
| 83 | Lubenau et al. | 2009 | Journal Article | Filgrastim | 72 | 336 h |
| 84 | Cho et al. | 2009 | Journal Article | rHuEPO (Aropotin) | 12 | 3 weeks |
| 85 | Togawa et al. | 2004 | Journal Article | rHuEPO (Epoetin alfa) | 30 | 21 days |
| 86 | Höglund et al. | 1997 | Journal Article | Filgrastim | 60 | 5 weeks |
| Neutropenia (NP) | ||||||
| 87 | Carlsson et al. | 2004 | Journal Article | Filgrastim | 8 | 60 weeks |
| 88 | Bonig et al. | 2001 | Journal Article | Filgrastim | 33 | 3 days |
| Cancer | ||||||
| 89 | Krendyukov et al. | 2017 | Journal Article | Filgrastim | 218 | 21 weeks |
| 90 | Verpoort and Möhler | 2012 | Journal Article | Filgrastim | 102 | 2.5 years |
BS biosimilar, GH human growth hormone, rHuEPO recombinant human erythropoietin, SC subcutaneous
Note: Citation numbers (first column in the above table) refer to the bibliography detailed in the Supplementary Material (Supplemental Table 12)